08:04 AM EDT, 09/24/2025 (MT Newswires) -- UniQure ( QURE ) said Wednesday it has entered into a $175 million senior secured term loan facility with Hercules Capital ( HTGC ) to finance the potential commercial launch of AMT-130, its investigational gene therapy for treating Huntington's disease.

The transaction includes $50 million to refinance existing debt, a $100 million additional loan tranche, contingent on certain regulatory and financial milestones, and a third tranche of up to $25 million, subject to Hercules Capital's ( HTGC ) approval, the company said.

The three tranches mature in October 2030, UniQure ( QURE ) added.